Updated National Liver Review Board guidance in effect Jan. 5, 2023
New pathway set for pediatric candidates with cystic fibrosis; guidance amended for candidates with hepatic adenoma and Budd-Chiari syndrome.
New pathway set for pediatric candidates with cystic fibrosis; guidance amended for candidates with hepatic adenoma and Budd-Chiari syndrome.
Basing MMaT scores around the donor hospital intended to promote greater patient access.
Effective Sept. 28, 2022, the median MELD at transplant (MMaT) values for liver transplant candidates with exception scores will be updated.
Report details outcomes since policy implementation in February 2020.
Updates made to guidance for HCC and adult MELD exceptions.
Four exclusion criteria in OPTN Policy 14.4.E have been updated to align with current research and guidelines as well as ensure consistency throughout OPTN policy language.